US Greenlights Novartis' $2.9B MorphoSys Takeover
Germany's MorphoSys AG said Friday it has received U.S. antitrust clearance for the biopharmaceutical company's planned $2.9 billion sale to Swiss Pharma giant Novartis AG, a development that clears the final...To view the full article, register now.
Already a subscriber? Click here to view full article